A Safety Study of XL019 in Adults With Myelofibrosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2007

Conditions
Myeloproliferative DisordersMyelofibrosisPolycythemia VeraThrombocythemia, Essential
Interventions
DRUG

XL019

gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths

Trial Locations (5)

10029

Mt. Sinai School of Medicine, New York

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

77030

MD Anderson Cancer Center, Houston

94143

UCSF - Division of Hematology/Oncology, San Francisco

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Exelixis

INDUSTRY